Wilmington, DE – According to filings with the U.S. Securities and Exchange Commission, Prelude Therapeutics is raising $49,999,969.00 in new funding. Sources indicate as part of senior management Chief Executive Officer, Kris Vaddi played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Prelude Therapeutics

Prelude was founded in 2016 with the vision of bringing together the energy and collaborative culture of a start-up environment with experience in developing cancer medicines to create a next generation cancer drug discovery company. Prelude is a privately-held, clinical-stage biopharmaceutical company designing and developing a pipeline of novel, orally bioavailable, small molecule therapies that target key drivers of cancer cell growth, survival and resistance. We are focused on closing the gap between emerging insights into resistance mechanisms in cancer and the needs of patients who either do not respond to or progress on current cancer treatments.

To learn more about Prelude Therapeutics, visit http://preludetx.com/

Contact:
Kris Vaddi, Chief Executive Officer
302-467-1280
https://www.linkedin.com/in/kris-vaddi-ph-d-7b41867/

SOURCE: http://www.intelligence360.io
Copyright (c) 2020 SI360 Inc. All rights reserved